Lancaster-based Simulations Plus entered a funded collaboration with an unnamed large pharmaceutical company that will enhance one of the company’s simulation software programs.
The collaboration will modify the GastroPlus Advanced Compartmental Absorption and Transit (ACAT) model, giving scientists a better understanding of drug disposition in the gastrointestinal tract and supporting research programs for the treatment of gastrointestinal diseases.
Financial terms of the deal were not disclosed.
“Our GastroPlus ACAT model has, time and again, been independently validated as the most accurate simulation engine for the prediction of oral absorption for drugs and chemicals across species and population groups,” Dr. Viera Lukacova, Simulation’s division chief scientific officer, said in a statement. “This new collaboration will accentuate GastroPlus functionality in local gut delivery through extensions to the mechanisms and physiological databases which underpin the ACAT model.”
The partnership marks Simulations’ second collaboration of 2022, as the company recently announced a partnership that expanded GastroPlus’ functionality to support veterinary medicine and food production research.
“Our second announced collaboration in 2022 dovetails perfectly with other active programs to enhance the GastroPlus ACAT model as the preeminent approach for predicting oral product performance, food effect considerations, pH-dependent drug-drug interaction risk and virtual bioequivalence assessment,” John DiBella, Simulations’ division president, said in a statement.
The company announced the partnership last week. Shares of Simulations Plus (SLP) closed Tuesday down $2.10, or 4.9 percent, to $40.95 on the Nasdaq, while that market closed down 2.3 percent.